Display options
Cite
Elshafey MR, Ahmed RA, Mourad MI, et al. The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. Cancer Biol Med. 2016;13(2):286-95doi: 10.20892/j.issn.2095-3941.2016.0037.
Elshafey, M. R., Ahmed, R. A., Mourad, M. I., & Gaballah, E. T. (2016). The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. Cancer biology & medicine, 13(2), 286-95. https://doi.org/10.20892/j.issn.2095-3941.2016.0037
Elshafey, Mohamed R, et al. "The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands." Cancer biology & medicine vol. 13,2 (2016): 286-95. doi: https://doi.org/10.20892/j.issn.2095-3941.2016.0037
Elshafey MR, Ahmed RA, Mourad MI, Gaballah ET. The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. Cancer Biol Med. 2016 Jun;13(2):286-95. doi: 10.20892/j.issn.2095-3941.2016.0037. PMID: 27458536; PMCID: PMC4944550.
Copy Download .nbib Format: NLM
Share it on

Cancer Biol Med. 2016 Jun;13(2):286-95. doi: 10.20892/j.issn.2095-3941.2016.0037.

The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands.

Cancer biology & medicine

Mohamed R Elshafey, Rehab A Ahmed, Mohamed I Mourad, Essam T Gaballah

Affiliations

  1. Oral Pathology Department, Faculty of Dentistry, Mansoura University, Mansoura 35516, Egypt.
  2. Pathology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.

PMID: 27458536 PMCID: PMC4944550 DOI: 10.20892/j.issn.2095-3941.2016.0037

Abstract

OBJECTIVE: Mucoepidermoid carcinoma (MEC) is the most common primary malignancy of the salivary glands. Insulin-like growth factor-II mRNA-binding protein-3 (IMP3) is an important prognostic factor in some cancers and a tool that differentiates between benign and malignant pancreatic lesions. This study aimed to identify a relationship between the expression of IMP3 and the outcome of salivary gland MEC, as well as to differentiate MEC from pleomorphic adenoma (PA).

METHODS: Tissue specimens from 70 cases of salivary gland MEC, 40 cases of PA, and 10 cases with normal salivary gland were examined immunohistochemically for IMP3. The association among the expression of IMP3, clinicopathological characteristics and patient's survival was assessed.

RESULTS: IMP3 was present in 51.4% of MEC but absent in PA and normal salivary gland tissues. IMP3 expression was associated with age > 60 years, submandibular gland tumors, tumor size > 4 cm, high-grade tumors, lymph node metastasis, involvement of surgical margins, perineural invasion, distant metastasis, advanced TNM stage, tumor relapse, and death ( P<0.05). Increased expression of IMP3, tumors of the submandibular gland, and lymph node metastasis were independent prognostic factors of -free survival (DFS). In addition, IMP3 was a strong predictor of overall survival (OS) together with distant metastasis and intermediate and high-grade tumors.

CONCLUSIONS: IMP3 expression is highly important in evaluating the outcome of MEC. IMP3 can be used to differentiate MEC from PA of salivary glands.

Keywords: IMP3; mucoepidermoid carcinoma; prognosis; salivary glands

References

  1. Clin Cancer Res. 2008 Mar 15;14(6):1701-6 - PubMed
  2. Am J Clin Pathol. 1984 Jun;81(6):696-701 - PubMed
  3. Am J Surg Pathol. 2008 Feb;32(2):304-15 - PubMed
  4. Br J Surg. 2009 Jan;96(1):66-73 - PubMed
  5. Cancer. 2008 Apr 1;112(7):1471-9 - PubMed
  6. J Med Genet. 2002 Aug;39(8):575-81 - PubMed
  7. Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):271-6 - PubMed
  8. Hepatology. 2008 Oct;48(4):1118-27 - PubMed
  9. Ann Surg Oncol. 2002 Aug;9(7):688-95 - PubMed
  10. Lancet Oncol. 2006 Jul;7(7):556-64 - PubMed
  11. Br J Cancer. 2003 Mar 24;88(6):887-94 - PubMed
  12. J Otolaryngol. 2003 Oct;32(5):328-31 - PubMed
  13. Cell Death Dis. 2014 Jan 23;5:e1025 - PubMed
  14. Mech Dev. 1999 Oct;88(1):95-9 - PubMed
  15. Head Neck. 2011 Mar;33(3):368-74 - PubMed
  16. Cancer. 2012 Aug 15;118(16):3928-36 - PubMed
  17. Jpn J Clin Oncol. 2008 Jun;38(6):414-8 - PubMed
  18. Am J Surg Pathol. 2005 Feb;29(2):188-95 - PubMed
  19. Cancer. 1998 Apr 1;82(7):1217-24 - PubMed
  20. Head Neck. 2011 Apr;33(4):497-503 - PubMed
  21. J Craniomaxillofac Surg. 2014 Dec;42(8):1891-6 - PubMed
  22. Arch Pathol Lab Med. 2000 Jan;124(1):87-91 - PubMed

Publication Types